

10849,088

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal201txs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 3 JAN 16 CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS 4 JAN 16 IPC version 2007.01 thesaurus available on STN
NEWS 5 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification
data
NEWS 6 JAN 22 CA/CAPLUS updated with revised CAS roles
NEWS 7 JAN 22 CA/CAPLUS enhanced with patent applications from India
NEWS 8 JAN 29 PHAR reloaded with new search and display fields
NEWS 9 JAN 29 CAS Registry Number crossover limit increased to 300,000
in
multiple databases
NEWS 10 FEB 15 PATDPASPC enhanced with Drug Approval numbers
NEWS 11 FEB 15 RUSSIAPAT enhanced with pre-1994 records
NEWS 12 FEB 23 KOREAPAT enhanced with IPC 8 features and functionality
NEWS 13 FEB 26 MEDLINE reloaded with enhancements
NEWS 14 FEB 26 EMBASE enhanced with Clinical Trial Number field
NEWS 15 FEB 26 TOXCENTER enhanced with reloaded MEDLINE
NEWS 16 FEB 26 IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 17 FEB 26 CAS Registry Number crossover limit increased from 10,000
to 300,000 in multiple databases
NEWS 18 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 19 MAR 16 CASREACT coverage extended
NEWS 20 MAR 20 MARPAT now updated daily
NEWS 21 MAR 22 LWPI reloaded
NEWS 22 MAR 30 RDISCLOSURE reloaded with enhancements
NEWS 23 APR 02 JICST-EPLUS removed from database clusters and STN
NEWS 24 APR 30 GENBANK reloaded and enhanced with Genome Project ID field
NEWS 25 APR 30 CHEMCATS enhanced with 1.2 million new records
NEWS 26 APR 30 CA/CAPLUS enhanced with 1870-1889 U.S. patent records
NEWS 27 APR 30 INPADOC replaced by INPADOCDB on STN
NEWS 28 MAY 01 New CAS web site launched

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

11/849,088

| | |
|------------|---|
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability |
| NEWS LOGIN | Welcome Banner and News Items |
| NEWS IPC8 | For general information regarding STN implementation of IPC 8 |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:02:14 ON 01 MAY 2007

=> file reg

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 15:02:29 ON 01 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 30 APR 2007 HIGHEST RN 933825-30-0

DICTIONARY FILE UPDATES: 30 APR 2007 HIGHEST RN 933825-30-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10849088.str

11/849,088



chain nodes :

20

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

chain bonds :

9-20 10-17 13-20

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-14 11-12
12-13 13-14 15-16 15-19 16-17 17-18 18-19

exact/norm bonds :

6-9 7-8 8-9 9-20 12-13

exact bonds :

5-7 10-11 10-14 10-17 11-12 13-14 13-20 15-16 15-19 16-17 17-18
18-19

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 : 10 : 15 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom
18:Atom 19:Atom 20:CLASS

11/849,088

L1 STRUCTURE UPLOADED

=> s l1

SAMPLE SEARCH INITIATED 15:02:50 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 16 TO ITERATE

100.0% PROCESSED 16 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
PROJECTED ITERATIONS: 80 TO 560
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> s l1 ful

FULL SEARCH INITIATED 15:02:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 264 TO ITERATE

100.0% PROCESSED 264 ITERATIONS 58 ANSWERS
SEARCH TIME: 00.00.01

L3 58 SEA SSS FUL L1

=> file caplus

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|---------------------|------------------|
| FULL ESTIMATED COST | 172.10 | 172.31 |

FILE 'CAPLUS' ENTERED AT 15:03:05 ON 01 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 May 2007 VOL 146 ISS 19
FILE LAST UPDATED: 30 Apr 2007 (20070430/ED)

11/849,088

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13

L4 1 L3

=> d 14 ibib hitstr abs

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:1011963 CAPLUS
DOCUMENT NUMBER: 142:6526
TITLE: Preparation of indazolecarboxamides as factor VIIa
and/or factor Xa inhibitors
INVENTOR(S): Nazare, Marc; Wehner, Volkmar; Laux, Volker;
Urmann,
Matthias; Bauer, Armin; Matter, Hans
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
SOURCE: Eur. Pat. Appl., 103 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|------------------|------------|
| EP 1479675 | A1 | 20041124 | EP 2003-11303 | 20030519 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| AU 2004238499 | A1 | 20041125 | AU 2004-238499 | 20040505 |
| CA 2528220 | A1 | 20041125 | CA 2004-2528220 | 20040505 |
| WO 2004101556 | A1 | 20041125 | WO 2004-EP4753 | 20040505 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1628972 | A1 | 20060301 | EP 2004-731155 | 20040505 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| BR 2004010430 | A | 20060606 | BR 2004-10430 | 20040505 |
| JP 2006528942 | T | 20061228 | JP 2006-529742 | 20040505 |
| US 2004235824 | A1 | 20041125 | US 2004-849088 ✓ | 20040519 |
| PRIORITY APPLN. INFO.: | | | EP 2003-11303 | A 20030519 |

US 2003-507171P P 20030930

WO 2004-EP4753 W 20040505

OTHER SOURCE(S): CASREACT 142:6526; MARPAT 142:6526

IT 797803-86-2P 797803-87-3P 797803-88-4P
797803-89-5P 797803-90-8P 797803-91-9P
797803-92-0P 797803-93-1P 797803-94-2P
797803-95-3P 797803-96-4P 797803-97-5P
797803-98-6P 797803-99-7P 797804-00-3P
797804-01-4P 797804-02-5P 797804-03-6P
797804-04-7P 797804-05-8P 797804-06-9P
797804-07-0P 797804-08-1P 797804-09-2P
797804-10-5P 797804-11-6P 797804-12-7P
797804-13-8P 797804-14-9P 797804-15-0P
797804-16-1P 797804-18-3P 797804-19-4P
797804-21-8P 797804-23-0P 797804-25-2P
797804-27-4P 797804-28-5P 797804-29-6P
797804-30-9P 797804-31-0P 797804-34-3P
797804-35-4P 797804-36-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)


(claimed compound; preparation of indazolecarboxamides as factor
VIIa and/or
factor Xa inhibitors)

RN 797803-86-2 CAPLUS

CN 1H-Indazole-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-

isoxazolyl)methyl]-3-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-,
methyl ester (9CI) (CA INDEX NAME)

11/849,088




RN 797803-87-3 CAPLUS

CN 1H-Indazole-6-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-

isoxazolyl]methyl]-3-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]-,
methyl ester (9CI) (CA INDEX NAME)

11/849,088




RN 797803-88-4 CAPLUS

CN 1H-Indazole-7-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-

isoxazolyl]methyl]-3-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]-,
methyl ester (9CI) (CA INDEX NAME)

11/849,088




RN 797803-89-5 CAPLUS

CN 1H-Indazole-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-

isoxazoly]methyl]-3-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-
(9CI) (CA INDEX NAME)

11/849,088




RN 797803-90-8 CAPLUS

CN 1H-Indazole-7-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-

isoxazolyl]methyl]-3-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]-
(9CI) (CA INDEX NAME)

11/849,088




RN 797803-91-9 CAPLUS

CN 1H-Indazole-6-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-

isoxazolyl]methyl]-3-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]-
(9CI) (CA INDEX NAME)

11/849,088




RN 797803-92-0 CAPLUS

CN 1H-Indazole-3-carboxamide,

1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-

N-[1-(1-methylethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)

11/849,088




RN 797803-93-1 CAPLUS

CN 1H-Indazole-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-

isoxazolyl]methyl]-3-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-,
1-[(ethoxycarbonyl)oxy]ethyl ester (9CI) (CA INDEX NAME)

11/849,088




RN 797803-94-2 CAPLUS

CN 1H-Indazole-3-carboxamide,

1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-

4-cyano-N-[1-(1-methylethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)

11/849,088




RN 797803-95-3 CAPLUS

CN 1H-Indazole-3-carboxamide,

1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-

4-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)-N-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

11/849,088



RN 797803-96-4 CAPLUS


CN 1H-Indazole-3-carboxamide, 5-(1-azetidinyldicarbonyl)-1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N-[1-(1-methylethyl)-4-piperidinyl]-
(9CI)

(CA INDEX NAME)

CC(C)N1CCN(CC1)NC(=O)c2nc3ccccc3n2Cn4cc5cc(Cl)cc5o4

CN 1H-Indazole-3,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N3-[1-(1-methylethyl)-4-piperidinyl]-N5-[2-(methylsulfonyl)ethyl]- (9CI) (CA INDEX NAME)

11/849,088




RN 797803-98-6 CAPLUS


CN 1H-Indazole-3,5-dicarboxamide,

N5-[2-(aminosulfonyl)ethyl]-1-[[5-(5-chloro-
2-thienyl)-3-isoxazolyl]methyl]-N3-[1-(1-methylethyl)-4-piperidinyl]-
(9CI) (CA INDEX NAME)

11/849,088




RN 797803-99-7 CAPLUS
CN 1H-Indazole-3,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N3-[1-(1-methylethyl)-4-piperidinyl]-N5-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 797804-00-3 CAPLUS

11/849,088


CN 1H-Indazole-3,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N3-[1-(1-methylethyl)-4-piperidiny]-N5-[(trimethylsilyl)methyl]- (9CI) (CA INDEX NAME)



RN 797804-01-4 CAPLUS

CN 1H-Indazole-3,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N5,N5-bis(2-hydroxyethyl)-N3-[1-(1-methylethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)

11/849,088




RN 797804-02-5 CAPLUS

CN 1H-Indazole-3,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-

isoxazolyl]methyl]-N5-(2-hydroxyethyl)-N5-methyl-N3-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


11/849,088



RN 797804-03-6 CAPLUS

CN Glycine, N-[[1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-3-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-1H-indazol-5-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)


11/849,088



RN 797804-04-7 CAPLUS

CN 1H-Indazole-3,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N5-(2,2-difluoroethyl)-N3-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

11/849,088




RN 797804-05-8 CAPLUS

CN 1H-Indazole-3,5-dicarboxamide,

N5-(2-amino-2-oxoethyl)-1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N3-[1-(1-methylethyl)-4-piperidinyl]-
(9CI)


(CA INDEX NAME)

11/849,088



RN 797804-06-9 CAPLUS


CN 1H-Indazole-3,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N5-(2-hydroxyethyl)-N3-[1-(1-methylethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)



RN 797804-07-0 CAPLUS

CN 1H-Indazole-3,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N5-[1-(1-methylethyl)-4-piperidiny]l]-N3-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI) (CA INDEX NAME)

11/849,088




RN 797804-08-1 CAPLUS

CN 1H-Indazole-3,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-

isoxazolyl)methyl]-N5-[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]-N3-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


11/849,088



RN 797804-09-2 CAPLUS

CN Glycine, N-[[1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-3-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-1H-indazol-5-yl]carbonyl]-
(9CI) (CA INDEX NAME)

11/849,088




RN 797804-10-5 CAPLUS

CN 2-Azetidinecarboxylic acid, 1-[[[1-[[5-(5-chloro-2-thienyl)-3-

isoxazolyl]methyl]-3-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]-1H-indazol-5-yl]carbonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 797804-11-6 CAPLUS

11/849,088


CN 1H-Indazole-3,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N3-[1-(1-methylethyl)-4-piperidiny]-N5-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 797804-12-7 CAPLUS

CN Glycine, N-[[1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-3-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]-1H-indazol-5-yl]carbonyl]-N-methyl- (9CI) (CA INDEX NAME)


11/849,088



RN 797804-13-8 CAPLUS

CN 1H-Indazole-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-3-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-, 2-hydroxyethyl ester (9CI) (CA INDEX NAME)

11/849,088




RN 797804-14-9 CAPLUS

CN 1H-Indazole-3-carboxamide,

1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-

N-[1-(1-methylethyl)-4-piperidyl]-5-[(tetrahydro-1,4-oxazin-4(5H)-yl)carbonyl]- (9CI) (CA INDEX NAME)

11/849,088




RN 797804-15-0 CAPLUS

CN 1H-Indazole-3-carboxamide,

1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-

5-[(3-hydroxy-1-azetidinyl)carbonyl]-N-[1-(1-methylethyl)-4-piperidinyl]-
(9CI) (CA INDEX NAME)

11/849,088




RN 797804-16-1 CAPLUS

CN 1H-Indazole-3,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N5-methoxy-N3-[1-(1-methylethyl)-4-piperidinyl]-
(9CI)

(CA INDEX NAME)

11/849,088





RN 797804-18-3 CAPLUS



CN 1H-Indazole-3-carboxamide,

1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-

N-[4-(1-pyrrolidinylcarbonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 797804-19-4 CAPLUS
 CN 1H-Indazole-3-carboxamide,
 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-
 N-[4-(4-morpholinylcarbonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 797804-21-8 CAPLUS
 CN Piperidine,
 1-[[1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-1H-indazol-3-yl]carbonyl]-4-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

11/849,088




RN 797804-23-0 CAPLUS

CN 1H-Indazole-3-carboxamide,

1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-

N-[4-(2-oxo-1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




/
Cl

RN 797804-25-2 CAPLUS

CN 1H-Indazole-3-carboxamide,

1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-


N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




/
Cl

RN 797804-27-4 CAPLUS
 CN 1H-Indazole-3-carboxamide,
 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-
 N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]- (9CI)
 (CA
 INDEX NAME)



PAGE 1-A




PAGE 2-A



RN 797804-28-5 CAPLUS
 CN 1H-Indazole-3-carboxamide,
 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-
 N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)





RN 797804-29-6 CAPLUS
 CN 1H-Indazole-3-carboxamide,
 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-
 N-[4-(1H-imidazol-4-yl)phenyl]- (9CI) (CA INDEX NAME)




/
Cl

RN 797804-30-9 CAPLUS
 CN 1H-Indazole-3-carboxamide,
 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-
 N-[4-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 797804-31-0 CAPLUS
 CN 1H-Indazole-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-3-[[[4-(3-oxo-4-morpholinyl)phenyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 797804-34-3 CAPLUS

CN 1H-Indazole-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-

isoxazolyl)methyl]-3-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-,
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester (9CI) (CA INDEX NAME)


11/849,088



RN 797804-35-4 CAPLUS

CN 1H-Indazole-3,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N5-cyano-N3-[1-(1-methylethyl)-4-piperidinyl]- (9CI)
(CA INDEX NAME)


11/849,088



RN 797804-36-5 CAPLUS

CN 3-Azetidinecarboxylic acid, 1-[[1-[[5-(5-chloro-2-thienyl)-3-

isoxazolyl]methyl]-3-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]-1H-indazol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)



IT 797804-39-8P 797804-40-1P 797804-42-3P
 797804-43-4P 797804-44-5P 797804-46-7P
 797804-47-8P 797804-49-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of indazolecarboxamides as factor VIIa and/or factor Xa
 inhibitors)

RN 797804-39-8 CAPLUS

CN 1H-Indazole-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-


isoxazolyl]methyl]-3-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]-,
 methyl ester, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 797803-86-2

CMF C26 H28 Cl N5 O4 S


11/849,088



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 797804-40-1 CAPLUS

CN 1H-Indazole-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-

isoxazolyl]methyl]-3-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]-,
hydrochloride (9CI) (CA INDEX NAME)

11/849,088




●x HCl

RN 797804-42-3 CAPLUS

CN 1H-Indazole-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-

isoxazolyl]methyl]-3-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]-,
1-[(ethoxycarbonyl)oxy]ethyl ester, hydrochloride (9CI) (CA INDEX
NAME)




●x HCl

RN 797804-43-4 CAPLUS
 CN 1H-Indazole-3-carboxamide,
 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-
 4-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)-N-[1-(1-methylethyl)-4-
 piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 797803-95-3
 CMF C26 H26 Cl N7 O4 S


11/849,088



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 797804-44-5 CAPLUS


CN 1H-Indazole-3-carboxamide, 5-(1-azetidinyldicarbonyl)-1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N-[1-(1-methylethyl)-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 797803-96-4

CMF C28 H31 Cl N6 O3 S


11/849,088



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 797804-46-7 CAPLUS

CN 1H-Indazole-3-carboxamide,


1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-

N-[4-(2-oxo-1-pyrrolidinyl)phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 797804-23-0

CMF C26 H20 Cl N5 O3 S




/
Cl

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 797804-47-8 CAPLUS

CN 1H-Indazole-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-3-[[[4-(3-oxo-4-morpholinyl)phenyl]amino]carbonyl]-,

11/849,088


methyl ester, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 797804-31-0

CMF C28 H22 Cl N5 O6 S

PAGE 1-A



PAGE 2-A




CM 2

CRN 76-05-1

CMF C2 H F3 O2

11/849,088



RN 797804-49-0 CAPLUS


CN 1H-Indazole-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-

isoxazolyl)methyl]-3-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-, (5-methyl-2-oxo-1,3-dioxolan-4-yl)methyl ester, hydrochloride (9CI)

(CA

INDEX NAME)

PAGE 1-A



PAGE 2-A

●x HCl

IT 797804-62-7

RL: RCT (Reactant); RACT (Reactant or reagent)

11/849,088

(preparation of indazolecarboxamides as factor VIIa and/or factor Xa inhibitors)

RN 797804-62-7 CAPLUS


CN 1H-Indazole-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-

isoxazolyl]methyl]-3-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]-, acetate (9CI) (CA INDEX NAME)

CM 1

CRN 797803-89-5


CMF C25 H26 Cl N5 O4 S



CM 2

CRN 64-19-7

CMF C2 H4 O2




IT 797804-51-4P 797804-57-0P 797804-58-1P
797804-59-2P

11/849,088

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
RACT
(Reactant or reagent)
(preparation of indazolecarboxamides as factor VIIa and/or factor Xa
inhibitors)


RN 797804-51-4 CAPLUS

CN 1H-Indazole-3,5-dicarboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-
isoxazolyl]methyl]-, 5-methyl ester (9CI) (CA INDEX NAME)



RN 797804-57-0 CAPLUS


CN 1H-Indazole-4-carbonitrile, 1-[[5-(5-chloro-2-thienyl)-3-
isoxazolyl]methyl]-3-formyl- (9CI) (CA INDEX NAME)




RN 797804-58-1 CAPLUS

CN 1H-Indazole-3-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-
isoxazolyl]methyl]-4-cyano- (9CI) (CA INDEX NAME)


11/849,088




RN 797804-59-2 CAPLUS
CN 1H-Indazole-3-carboxamide,
1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-
4-[(hydroxyamino)iminomethyl]-N-[1-(1-methylethyl)-4-piperidinyl]-
(9CI)
(CA INDEX NAME)



GI



I



II

AB Title compds. [I, II; R = (substituted) mono- or bicyclic aryl, heterocyclyl; D = atoms to form a (substituted) 4-8 membered (heterocyclic) (aromatic) ring; R1 = H, (substituted) alkyl, aminocarbonylalkyl, alkoxy carbonylalkyl, aryl, heterocyclyl, etc.; R2 = bond, alkylene; V = (substituted) heterocyclyl, aryl; G = bond, (CH2)mNR10SO2(CH2)n, (CH2)mNR10SO2(CH2)n, (CH2)mCH(OH)(CH2)n, (CH2)m, (CH2)mO(CH2)n, (CH2)mS(CH2)n, etc.; m, n = 0-6; R10 = H, alkyl, hydroxyalkyl, alkoxyalkyl, perfluoroalkyl, with provisos], were prepared

Thus, 1-[5-(5-chlorothien-2-yl)isoxazol-3-ylmethyl]-5-(cyanamide-1-carbonyl)-1H-indazole-3-carboxylic acid

(1-isopropylpiperidin-4-yl)amide

(preparation outlined) inhibited factor Xa with Ki = .5 nM.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

=> log y

COST IN U.S. DOLLARS

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 5.74 | 178.05 |

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| -0.78 | -0.78 |

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 15:03:30 ON 01 MAY 2007